Change at the Top of IDT Biologika – Dr. Ulrich Valley Becomes Sole CEO

Blog Post Date: Tuesday 23 April 2024

Dessau-Rosslau (Germany) and Rockville, MD (USA), April 22, 2024 – IDT Biologika, a leading contract development and manufacturing organization (CDMO) specialized in viral vaccines, viral vectors for cell and gene therapy as well as oncolytic viruses and other biologics, announces that Dr. Ulrich Valley has been appointed sole CEO of the company with effect from March 1, 2024.

Dr. Ulrich Valley joined IDT Biologika in October 2022 as Chief Operating Officer and was appointed second Managing Director.

Dr. Ulrich Valley, CEO IDT Biologika

 Dr. Ulrich Valley has almost 25 years of experience in the international pharmaceutical industry. He was previously Senior Vice President of Operations and Managing Director of KBI Biopharma in Geneva, Switzerland and also managed the site in Leuven, Belgium. Prior to that, he held various management positions at Novartis and Sandoz as site manager (U.S., Austria) and in global roles with a focus on Operations, Supply Chain and Development.

The previous CEO, Dr. Jürgen Betzing, has agreed with the shareholders to terminate his management mandate and leave the company. He has played a key role in shaping the company’s development over the past five years.

The shareholders would like to thank Dr. Jürgen Betzing for his commitment over the past years and congratulate Dr. Ulrich Valley on his appointment as sole Managing Director.